TY - JOUR TI - Morphological and immunohistochemical evaluation of interface lesions between chronic lymphocytic thyroiditis and papillary thyroid cancers AB - Objective: To evaluate the expression of papillary thyroid carcinoma-associated tumor markers in reactive and dysplastic changes showing papillary thyroid carcinoma-like nuclear features in chronic lymphocytic thyroiditis cases. Material and Method: In this study, we retrospectively analyzed 84 cases diagnosed with chronic lymphocytic thyroiditis based on the analysis of thyroidectomy specimens in our center over the last five years. We classified them as normal, reactive and dysplastic changes and performed an immunohistochemical analysis using HBME-1, Galectin-3, Cytokeratin 19, and Cyclin D1. Results: The mean age of the patients was 45.5 years, and 68 were female and 16 were male. According to the morphological features, 42.9% of the were classified to have normal morphology, 44.0% reactive atypia, and 13.1% follicular epithelial dysplasia (FED). Of the chronic lymphocytic thyroiditis cases, 42.9% were associated with malignancy, with the most common accompanying malignancy being papillary thyroid cancer (36.9%). Immunohistochemically: for HBME-1, FED (72.7%) was higher (p<0.05) than normal and reactive atypia (0.0%); for Galectin-3, FED (63.6%) was higher (p<0.05) than normal and reactive atypia (0.0%); for Cytokeratin 19, Reactive atypia (75.7%) and FED (90.9%) were higher than normal (44.4%); and for Cyclin-D1, Reactive atypia (62.2%) and FED (81.8%) were higher than normal (33.3%). Conclusions: We consider that reactive and dysplastic changes including papillary thyroid carcinoma-like nuclear changes may support preneoplastic changes in terms of morphology and immunoprofile in chronic lymphocytic thyroiditis cases. AU - bigat, irem AU - Celepli, Pınar AU - celepli, salih DO - 10.32322/jhsm.1052732 PY - 2022 JO - Journal of health sciences and medicine (Online) VL - 5 IS - 2 SN - 2636-8579 SP - 552 EP - 557 DB - TRDizin UR - http://search/yayin/detay/1156329 ER -